AIG
PRLD icon

American International Group’s Prelude Therapeutics PRLD Stock Holding History

American International Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,333
Closed -$34.8K – 2046
2024
Q1 		$34.8K Sell
7,333
-64
-0.9% -$249 ﹤0.01% 2855
2023
Q4 		$31.6K Buy
7,397
+295
+4% +$898 ﹤0.01% 2901
2023
Q3 		$21.9K Buy
7,102
+2,330
+49% +$8.74K ﹤0.01% 2977
2023
Q2 		$21.5K Buy
+4,772
New +$28.5K ﹤0.01% 3012
2022
Q2 		– Sell
-5,373
Closed -$37K – 3227
2022
Q1 		$37K Sell
5,373
-378
-7% -$3.46K ﹤0.01% 2936
2021
Q4 		$72K Sell
5,751
-172
-3% -$2.8K ﹤0.01% 2847
2021
Q3 		$185K Sell
5,923
-141
-2% -$4.57K ﹤0.01% 2475
2021
Q2 		$174 Buy
6,064
+288
+5% +$10.3K ﹤0.01% 2600
2021
Q1 		$250 Buy
5,776
+438
+8% +$29.1K ﹤0.01% 2249
2020
Q4 		$382 Buy
+5,338
New +$265K ﹤0.01% 1900

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

American International Group's PRLD Position: Q2 2024 in Review

American International Group sold out of Prelude Therapeutics (PRLD) in Q2 2024, closing a stake of 7,333 shares — an estimated $34.8K sold.

American International Group first reported a position in PRLD in Q4 2020 and held it in 10 quarters. The position peaked at $185K in Q3 2021. 61 funds tracked by Wall St. Rank hold PRLD as of Q2 2024.

  • American International Group reported no remaining Prelude Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 7,333 Prelude Therapeutics shares in Q2 2024, an estimated $34.8K.
  • American International Group first reported a position in Prelude Therapeutics in Q4 2020 and held it in 10 quarters.
  • American International Group's Prelude Therapeutics position peaked at $185K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.